Document is current

Any future updates will be listed below

Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis

Crossref DOI link: https://doi.org/10.1007/s11255-025-04771-0

Published Online: 2025-09-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark